Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples. Issue 1 (February 2022)

• Record Type: Journal Article
• Authors: Gürün Kaya, Aslıhan; Çiledağ, Aydın; Erol, Serhat; Öz, Miraç; Doğan Mülazımoğlu, Deniz; Işık, Özlem; Özakıncı, Hilal; Çiftçi, Fatma; Şen, Elif; Ceyhan, Koray; Kaya, Akın; Karnak, Demet; Çelik, Gökhan; İsmail, Savaş
• Is Part Of: Scottish medical journal. Volume 67:Issue 1(2022)
• Page Start: 18
• Page End: 27
• Publication Date: 2022-02
• Subjects: Non-small cell lung carcinoma -- lung cancer biomarker -- molecular analysis -- endobronchial ultrasound -- targeted therapy; Medicine -- Periodicals; 610.5
• DOI: 10.1177/00369330221078995
• Languages: English
• ISSNs: 0036-9330

Abstract

Background: Guidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject. Aim: The purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers. Methods: We retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020. Results: A total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing. Conclusion: EBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.